


Ask a doctor about a prescription for QUETIAPINE VIATRIS 25 mg FILM-COATED TABLETS
Package Leaflet: Information for the Patient
Quetiapine Viatris 25 mg Film-Coated Tablets EFG
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
Quetiapine Viatris contains a substance called quetiapine. It belongs to a group of medications called antipsychotics. Quetiapine can be used to treat several diseases, such as:
Your doctor may continue to prescribe quetiapine to you even when you are feeling better.
Do not take Quetiapine Viatris:
Do not take quetiapine if the above applies to you. If you have any doubts, consult your doctor or pharmacist before taking quetiapine.
Warnings and Precautions
Consult your doctor or pharmacist before starting to take quetiapine if:
Tell your doctor immediatelyif, after taking quetiapine, you experience any of the following:
These disorders may be caused by this type of medication.
Tell your doctor as soon as possible if you have:
Suicidal thoughts and worsening of your depression
If you are depressed, you may sometimes think about harming yourself or committing suicide. This can increase when you start treatment, as all these medications take time to work, usually around two weeks, but sometimes longer. These thoughts can also increase if you stop taking your medication abruptly. You may be more likely to think this way if you are a young adult. Clinical trial information has shown an increased risk of suicidal behavior and/or thoughts in young adults under 25 years of age with depression.
If you have had thoughts of harming yourself or committing suicide at any time, contact your doctor or go to a hospital immediately. It may be helpful to tell a close family member or friendthat you are depressed and ask them to read this package leaflet. You can ask them to tell you if they think your depression is getting worse, or if they are concerned about changes in your behavior.
Severe skin reactions (SCARs)
With the use of this medication, very rare but potentially life-threatening or fatal severe skin reactions (SCARs) have been reported. These are commonly manifested as:
If you develop these symptoms, stop using quetiapine and contact your doctor or seek medical attention immediately.
Weight gain
Weight gain has been observed in patients taking quetiapine. You and your doctor should monitor your weight regularly.
Children and adolescents
Quetiapine should not be used in children and adolescents under 18 years of age.
Other medications and Quetiapine Viatris
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medication.
Do not take quetiapine if you are using any of the following medications:
Consult your doctor if you are using any of the following medications:
Before stopping any of your medications, consult your doctor first.
Taking Quetiapine Viatris with food, drinks, and alcohol
Be careful with the amount of alcohol you drink. This is because the combined effect of quetiapine and alcohol can make you drowsy.
Do not drink grapefruit juice while taking quetiapine. It may affect how the medication works.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication. You should not take quetiapine during pregnancy, unless you have discussed it with your doctor. You should not use quetiapine if you are breastfeeding.
The following symptoms, which may represent a withdrawal syndrome, may appear in newborns of mothers who have used quetiapine in the last trimester (last three months of pregnancy): tremors, muscle stiffness, and/or weakness, drowsiness, agitation, breathing problems, and difficulty feeding. If your newborn develops any of these symptoms, you should contact your doctor.
Driving and using machines
These tablets may make you feel drowsy. Do not drive or operate tools or machines until you know how the tablets affect you.
Quetiapine Viatris contains lactose and sodium
Quetiapine Viatris contains
This medication contains less than 1 mmol of sodium (23 mg) per tablet; this is, essentially "sodium-free".
Effect on urine drug screening tests
If you are undergoing a urine drug screening test, taking quetiapine may produce positive results for methadone or certain antidepressant medications called tricyclic antidepressants (TCAs) when some analysis methods are used, even if you are not taking methadone or TCAs. If this happens, a more specific test can be performed.
Follow your doctor's instructions for taking this medication exactly. If you have any doubts, consult your doctor or pharmacist again.
Your doctor will decide your initial dose. The maintenance dose (daily dose) will depend on your disease and needs, but it is usually between 150 mg and 800 mg.
Liver problems
If you have liver problems, your doctor may change your dose.
Elderly people
If you are an elderly patient, your doctor may change your dose.
Use in children and adolescents
Quetiapine should not be used in children and adolescents under 18 years of age.
If you take more Quetiapine Viatris than you should
If you take more quetiapine than your doctor has prescribed, you may feel drowsy, dizzy, and experience abnormal heartbeats, dry mouth, constipation, dilated pupils, or blurred vision. Contact your doctor or the nearest hospital immediately. Bring the package and any remaining tablets with you.
You can also call the Toxicology Information Service, phone 915620420, indicating the medication and the amount taken.
If you forget to take a dose of Quetiapine Viatris
If you forget to take a dose, take it as soon as you remember. If it is almost time for your next dose, wait until then. Do not take a double dose to make up for the missed tablet.
If you stop taking Quetiapine Viatris
If you stop taking quetiapine abruptly, you may be unable to sleep (insomnia), feel nauseous, or experience headaches, diarrhea, vomiting, dizziness, or irritability. Your doctor may suggest gradually reducing the dose before stopping treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Contact a doctor IMMEDIATELY if you develop any of the following adverse effects:
Very Common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Very Rare(may affect up to 1 in 10,000 people):
Frequency Not Known(frequency cannot be estimated from available data):
The class of medicines to which quetiapine belongs can cause heart rhythm problems that can be serious and, in severe cases, can be fatal.
Some adverse effects are only observed when a blood test is performed. These include increases in the amount of certain fats (triglycerides and total cholesterol) or sugar in the blood, changes in the amount of thyroid hormones in the blood, increased liver enzymes, decreases in the number of certain types of blood cells, decreased red blood cell count, increased creatine phosphokinase in the blood (a muscle substance), decreased sodium levels in the blood, and increased prolactin hormone levels in the blood.
Your doctor may ask you to have blood tests from time to time.
Adverse Effects in Children and Adolescents:
The same adverse effects that can occur in adults can also occur in children and adolescents.
The following adverse effects have been observed more frequently in children and adolescents or have not been observed in adults:
Very Common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this leaflet. You can also report them directly through the Spanish Medicines and Health Products Agency (AEMPS) https://www.aemps.gob.es/.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging after CAD or EXP. The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Medicines should not be disposed of through wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE collection point in your pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Quetiapine Viatris
The active ingredient is quetiapine fumarate.
Each film-coated tablet contains 25 mg of quetiapine (as quetiapine fumarate).
The other ingredients are: lactose monohydrate, microcrystalline cellulose (E-460), povidone 30, magnesium stearate (E-572), sodium carboxymethyl starch (type A) derived from potato starch, and calcium hydrogen phosphate dihydrate. Tablet coating: hypromellose (E-464), titanium dioxide (E-171), macrogol 400, and red iron oxide (E-172).
Appearance of the Product and Package Contents
Quetiapine Viatris is presented in the form of film-coated tablets.
The tablets are round, peach-colored, biconvex, with the inscription "Q" on one face.
The tablets are available in blisters of 1, 3, 6, 7, 10, 14, 20, 28, 30, 50, 56, 60, 84, 90, 98, 100, 6 × 1, 60 × 1 tablets, and in bottles of 60, 84, 90, 98, 100, 250, 500, and 1000 tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Viatris Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland
Manufacturer
McDermott Laboratories Ltd. t/a Gerard Laboratories
35/36 Baldoyle Industrial Estate
Grange Road
Dublin 13
Ireland
Or
Generics [UK] Limited
Station Close, Potters Bar
Hertfordshire, EN6 1TL
United Kingdom
Or
Mylan Hungary Kft.
Mylan utca 1.
2900 Komáron
Hungary
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Viatris Pharmaceuticals, S.L.U.
C/ General Aranaz, 86
28027 - Madrid
Spain
This medicine is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) with the following names:
Belgium Quetiapine Viatris 25 mg film-coated tablets
Cyprus Quetiapine/Viatris 25 mg film-coated tablets
Denmark Quetiapin Viatris film-coated tablets 25 mg
Spain Quetiapina Viatris 25 mg film-coated tablets EFG
Greece Quetiapine/Viatris
Iceland Quetiapin Viatris 25 mg film-coated tablets
Ireland Geroquel 25 mg film-coated tablets
Malta Quetiapine/VIATRIS 25 mg film-coated tablets
Netherlands Quetiapine Viatris 25 mg film-coated tablets
Poland Etiagen
Portugal Quetiapina Mylan
United Kingdom
(Northern Ireland) Quetiapine 25 mg film-coated tablets
Czech Republic Quetiapin Viatris
Date of the Last Revision of this Leaflet:June 2024.
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) https://www.aemps.gob.es/.
The average price of QUETIAPINE VIATRIS 25 mg FILM-COATED TABLETS in November, 2025 is around 2.5 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for QUETIAPINE VIATRIS 25 mg FILM-COATED TABLETS – subject to medical assessment and local rules.